Taprenepag
Taprenepag, also known as CP-544326, is a potent and selective EP (2) receptor agonist, was successfully evaluated for its ocular hypotensive activity in a clinical study involving patients with primary open angle glaucoma. Taprenepag is the active metabolite of PF-04217329. (In Vitro) :Taprenepag (CP-544326) (0.01-1000 nM) increases cAMP levels in HEK293 cells expressing human EP2 (EC50=2.8 nM) . Taprenepag has poor corneal permeability in an ex vivo rabbit corneal model.
Product Specifications
CAS Number
752187-80-7
Product Name Alternative
CP-544326 | CP544326, Taprenepag, PF-0421732 metabolite
Purity
>98% (HPLC)
Solubility
DMSO : ≥ 31 mg/mL; 64.78 mM
Smiles
C1cc (cc (c1) OCC (=O) O) CN (Cc1ccc (cc1) n1cccn1) S (=O) (=O) c1cnccc1
Molecular Formula
C24H22N4O5S
Molecular Weight
478.52
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2- (3- ((N- (4- (1H-pyrazol-1-yl) benzyl) pyridine-3-sulfonamido) methyl) phenoxy) acetic acid
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
